Study of PTCH1 Gene as a Prognostic Marker to Predict Imatinib Response in CML Patients: a Single Egyptian Center Experience | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 39, Volume 84, Issue 1, July 2021, Pages 1875-1879 PDF (261.69 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2021.178590 | ||
| Authors | ||
| Mohamed Mahmoud Moussa; Mohamed Tarif Hamza; Omnia Shoukry Abdel Fattah; Mary Gamal Naguib* | ||
| Abstract | ||
| Background: Chronic myeloid leukemia (CML) is a myeloproliferative illness marked by a reciprocal translocation between chromosomes 9 and 22 [t (9;22) (q34; q11)], forming the Philadelphia chromosome and bringing together the Breakpoint Cluster Region (BCR) and Abelson (ABL1) genes. The protein expressed by this fusion gene is a dysregulated tyrosine kinase that causes alterations in cell proliferation, DNA repair, differentiation, and cell cycle by phosphorylating many downstream proteins. Objectives: To assess PTCH1 gene expression and response of adult patients with chronic myeloid leukemia to imatinib treatment. Patients and Methods: This is a prospective case-control study that included 55 subjects; 45 patients with chronic phase chronic myeloid leukemia and 10 healthy age and sex-matched controls. The control group presented from the same geographic origin of the patients in the study group. The study was done between June 2015 and July 2017 at the hematology clinic, Ain Shams University Hospital. Results: PTCH1 gene was more in cases than control with a statistical significance (P-value=0.024). On following up our cases after 6 months treatment with imatinib, patients with desired response to imatinib treatment had a mean of PTCH1 gene expression of 2.41, compared to 3.58 in patients who did not achieve desired response with a statistical significance with p-value = 0.017. Incidence of imatinib failure after 6 months of treatment in patients with high PTCH1 expression is 27.8 % while in those with low expression is 44.4 %. Conclusion: The study demonstrates that level of PTCH 1 did not affect imatinib response. Therefore, PTCH1 is not a valid biomarker for imatinib resistance in CML patients. | ||
| Keywords | ||
| Chronic Phase; Egyptian CML Patients; Predict Imatinib Response; Prognostic Marker; PTCH1 Gene | ||
|
Statistics Article View: 230 PDF Download: 375 |
||
